Novo Nordisk Eli Lilly Lawsuit: What the Case Turns On
Witfire Elite · Litigation Risk Brief · GLP-1 Series No. 04 Novo Nordisk vs Eli Lilly: The Obesity Ad War Neither Side Can Win…
Witfire Coverage
Category: FDA & Regulatory Intelligence
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma
Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA Rejects Replimune’s RP1 Despite 34% Response…
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug
Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study FDA & Regulatory Intelligence Witfire Elite View FTX-6058 and Pociredir FDA’s PRC2 Risk…
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections
Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View IQVIA Signal: Wegovy Pill May Expand the GLP-1…
FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I
Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA’s Digital Liver Break How AI Toxicology…